complement-c5

Complement C5-IN-1 is a small-molecule inhibitor of complement component 5 protein (C5).

Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds to human complement protein C5 with high affinity, targeting complement factor 5 to block complement activation. It can be used for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis.

Anti-Complement C5aR1 Antibody is a human-derived antibody expressed in CHO cells, targeting C5AR/C5AR1/C5R1. It features a huIgG1 heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 146.4 kDa. For isotype control, refer to Human IgG1 kappa, Isotype Control.

Zilucoplan(PEG2) is a derivative of Zilucoplan where the linker component has been substituted with PEG2 instead of PEG24. This compound acts as an effective inhibitor of complement component 5 (C5).

Cemdisiran, an investigational N-acetylgalactosamine-conjugated RNAi (RNA interference) agent with terminal sugar modification, is a small interfering RNA (siRNA) designed to specifically target and suppress the C5 mRNA, thereby reducing the liver's production of the complement component C5 [1].

ARC1905, a non-PEGylated/naked anti-C5 RNA aptamer, functions by inhibiting the cleavage of complement factor 5 (C5) into its components, C5a and C5b, without PEG conjugation. This compound is currently being researched for its potential application in the treatment of age-related macular degeneration (AMD).

ARC186 is a highly potent aptamer that serves as a complement inhibitor by blocking the convertase-catalyzed activation of C5.

Zilucoplan (RA101495), a 15-amino acid macrocyclic peptide and potent complement component 5 (C5) inhibitor, is used in the study of immune-mediated necrotising myopathy (IMNM) [1] [2].

Gefurulimab (ALXN-1720) is a human-derived bispecific antibody that targets complement C5 and albumin, specifically binding to C5 to inhibit its activation [1].

Pexelizumab (h5G1.1-SC), a humanized scFv monoclonal antibody, targets the C5 complement component, thereby inhibiting apoptosis and leukocyte infiltration. It is utilized in researching cerebral ischemia-reperfusion (IR) injury and myocardial infarction [1] [2].

NH2-C6-ARC186 is a derivative of the aptamer ARC186, featuring an NH2-C6 moiety that enables coupling to various peptides or molecules. As a potent complement inhibitor, it operates by inhibiting convertase-mediated C5 activation [1].

Zilucoplan TFA (RA101495), a 15-amino acid macrocyclic peptide, is a potent inhibitor of complement component 5 (C5) with applications in studying immune-mediated necrotising myopathy (IMNM) [1] [2].

Vensobafusp alfa (KP-104) is a fusion protein composed of an IgG4 monoclonal antibody targeting complement protein C5, combined with the domains 1-5 of complement factor H (FH1-5). It exhibits anti-inflammatory and immunomodulatory properties. The isotype control for Vensobafusp alfa can be referred to as human IgG4(S228P) kappa.

Boc-Leu-Gly-Arg-AMC is a specific fluorogenic substrate designed for the enzymatic detection and quantification of complement component C3/C5 convertases, coagulation factor Xa, and soybean trypsin-like enzyme activity. Boc-Leu-Gly-Arg-AMC is also susceptible to hydrolysis by macropain, a high molecular weight thiol proteinase isolated from human erythrocytes, making it a versatile tool for enzymatic assays.

C5 Protein (human) is a naturally glycosylated polypeptide composed of two disulfide-linked chains. It is essential for the formation of the membrane attack complex (MAC) and is activated via all three pathways of complement activation.